New drug combo shows promise in shrinking skin cancer before surgery

NCT ID NCT06288191

Recruiting now Disease control Sponsor: Melanoma Institute Australia Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving two immunotherapy drugs (nivolumab and relatlimab) before surgery can shrink or eliminate skin cancer in people with stage II to IV cutaneous squamous cell carcinoma. About 20 adults will receive the drugs for 6 weeks, then have surgery to remove any remaining cancer. The main goal is to see how many patients have no cancer cells left in the removed tissue.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

skin squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CUTANEOUS SQUAMOUS CELL CARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Melanoma Institute Australia
RECRUITING

Wollstonecraft, New South Wales, 2065, Australia

Contact Phone: •••-•••-•••• Email: •••••@•••••